CERO — CERo Therapeutics Holdings, Inc.
$0.01
+$0.00 (+25.00%)
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors.
Market Cap
$358154.00
Forward P/E
-0.0x
52-Week Range
N/A
CERO Price History
Revenue vs. Net Income
$0
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$16.1M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
0.4x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
4.2M
Diluted shares · FY2025
Only one year of share data is available, so no change can be shown yet.
